Generic Imatinib - CML - Chronic Myeloid Leukemia
The introduction of Imatinib Mesylate (Gleevec®), a tyrosine kinase inhibitor (TKI), has revolutionized the management of Chronic Myeloid Leukemia (CML). In 2013, Health Canada approved two generic versions of imatinib mesylate (Apotex and TEVA) for sale in Canada—both of which, have been shown to be bioequivalent to the brand name Gleevec®, with similar serum imatinib levels and area under the curve after oral ingestion.
Extract of Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia
VIDEOS
CML Horizons 2020 Advocacy #2: Generics - is the concern justified?
November 2020, CML Advocates Network
Generic Imatinib: Gaining Perspective
November 25, 2019, The Life Raft Group
Starting first-line treatment, update on Imatinib
October 11, 2019, CML Support Group UK
Generic vs. branded imatinib for CP-CML: a multicenter, observational study
December 17, 2018, VJHemOnc – Video Journal of Hematological Oncology
Imatinib, where are we now? What about generic Imatinib? Dr Joanne Ewing
September 25, 2018, CML Support Group UK
CML - Generic TKI's medication
April 19, 2018, Chronic Myeloid Leukaemia CML UK Facebook Group
Jorge Cortes, MD, on how generic imatinib is being adopted as an alternative to branded imatinib
December 18, 2017, OBRoncology
Generics for chronic myeloid leukemia treatment – a hot topic at ASH 2016 as imatinib patent expires
February 24, 2017, VJHemOnc – Video Journal of Hematological Oncology
Imatinib Generics in Treatment of Chronic Myeloid Leukemia
December 5, 2016, Cancer Therapy Advisor
Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML
October 8, 2016, OncLive
Dr. Jerald Radich on Impact of Generic Imatinib in CML
October 1, 2016, OncLive
Safety and efficacy of imatinib generics
August 3, 2016, ecancer
The practicalities of treating CML with generic therapies - Experience and recommendations - Jeff Lipton
2016, iCMLf
Dr. Hagop M. Kantarjian on the Generic Formulation of Imatinib
December 2, 2012, Targeted Oncology
CML Horizons 2020 Advocacy #2: Generics - is the concern justified?
November 2020, CML Advocates Network
Generic Imatinib: Gaining Perspective
November 25, 2019, The Life Raft Group
Starting first-line treatment, update on Imatinib
October 11, 2019, CML Support Group UK
Generic vs. branded imatinib for CP-CML: a multicenter, observational study
December 17, 2018, VJHemOnc – Video Journal of Hematological Oncology
Imatinib, where are we now? What about generic Imatinib? Dr Joanne Ewing
September 25, 2018, CML Support Group UK
CML - Generic TKI's medication
April 19, 2018, Chronic Myeloid Leukaemia CML UK Facebook Group
Jorge Cortes, MD, on how generic imatinib is being adopted as an alternative to branded imatinib
December 18, 2017, OBRoncology
Generics for chronic myeloid leukemia treatment – a hot topic at ASH 2016 as imatinib patent expires
February 24, 2017, VJHemOnc – Video Journal of Hematological Oncology
Imatinib Generics in Treatment of Chronic Myeloid Leukemia
December 5, 2016, Cancer Therapy Advisor
Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML
October 8, 2016, OncLive
Dr. Jerald Radich on Impact of Generic Imatinib in CML
October 1, 2016, OncLive
Safety and efficacy of imatinib generics
August 3, 2016, ecancer
The practicalities of treating CML with generic therapies - Experience and recommendations - Jeff Lipton
2016, iCMLf
Dr. Hagop M. Kantarjian on the Generic Formulation of Imatinib
December 2, 2012, Targeted Oncology
ARTICLES
Comparison of Generic and Branded Imatinib for Patients With Chronic Myeloid Leukemia
October 26, 2021, Hematology Advisor
Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs
September 3, 2021, Blood Advances
CML Treatment Costs Continue to Rise Despite Availability of Generic Imatinib
October 13, 2020, AJMC
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
September 30, 2020, NCBI
Generic Drugs for CML Ease the Cost of Treatment
September 16, 2020, Patient Power
Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center
January 27, 2020, PubMed
Q&A: Generic imatinib
January 16, 2020, Leukaemia Foundation
Despite lower price of generic imatinib, overall costs for chronic myeloid leukemia remain high
December 20, 2019, Healio
Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study
November 13, 2019, Blood
Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?
November 13, 2019, ASH 2019
Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study
November 13, 2019, ASH2019
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
November 2019, Am Health Drug Benefits
Generic Imatinib Comparable to Original in Treatment of Chronic Myeloid Leukemia
October 11, 2019, Oncology Nurse Advisor
ASH report on news about generic imatinib
October 2, 2019, The CML Advocates Network
Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
February 19, 2019, Cancer Therapy Advisor
Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study
January 10, 2019, Haematologica
Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries
December 2, 2018, Cancer Therapy Advisor
Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study
December 1, 2018, ASH 2018
Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study
December 1, 2018, ASH 2018
Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study
December 2017, ASH2017
Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia
December 2017, ASH2017
Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia
July 2017, PubMed
Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing
April 2017, JCO Oncology Practice - ASCO
CML: First-line Generic Imatinib May Be Inferior to Branded Imatinib
February 23, 2017, Cancer Therapy Advisor
The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients
February 16, 2017, Clinical Lymphoma Myeloma& Leukemia
The Comparison of Efficacy Between Generic and Branded Imatinib in Achievement of Overall Survival and Cytogenetic Responses in CML Patients in Bosnia and Herzegovina
2016, Journal Blood
Outcome of Frontline Treatment with Generic Imatinib in Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A First Multicenter Study
December 3, 2016, ASH 2016
Incorporating Generic Imatinib Into Frontline Treatment for CML
October 1, 2016, OncLive
Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer
August 26, 2016, Nature
Safety and efficacy of imatinib generics
August 3, 2016, ecancer
Modest Price Cut Expected For Generic Version Of Cancer Pill Gleevec®
February 1, 2016, NPR
The generics vs. Gleevec®
December 21, 2015, The Canadian CML Network
Is generic mesilate of imatinib less inferior than Glivec® ? Analisys in brazilian cohort?
June 2015, European Hematology Association
Outcome of frontline treatment with generic imatinib according to ELN 2009 based national guidelines. Experience of frontline treatment with generic imatinib. Experience from university clinic of hematology, Clinical center of Serbia, Belgrade
June 2015, European Hematology Association
Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia
June 2015, 2015 ASCO Annual Meeting
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
March 26, 2015, Europe PMC
Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia
2015, Journal Blood
Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia
December 6, 2014, Blood
Does the use of generics of imatinib for chronic myeloid leukaemia jeopardise patient safety?
July 7, 2014, ecancer
If Novartis’s “improved” version of Glivec® is not more therapeutically efficacious, why is the Novartis decision such a big deal?
April 11, 2013, Havard Law
Canada: Pharma In Brief - Canada: Federal Court Upholds Validity Of GLEEVEC® Patent
February 27 2013, Mondaq
Europe set to approve first Glivec® generic - PMLiVE
October 22, 2012, PMLive
Comparison of Generic and Branded Imatinib for Patients With Chronic Myeloid Leukemia
October 26, 2021, Hematology Advisor
Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs
September 3, 2021, Blood Advances
CML Treatment Costs Continue to Rise Despite Availability of Generic Imatinib
October 13, 2020, AJMC
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
September 30, 2020, NCBI
Generic Drugs for CML Ease the Cost of Treatment
September 16, 2020, Patient Power
Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center
January 27, 2020, PubMed
Q&A: Generic imatinib
January 16, 2020, Leukaemia Foundation
Despite lower price of generic imatinib, overall costs for chronic myeloid leukemia remain high
December 20, 2019, Healio
Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study
November 13, 2019, Blood
Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?
November 13, 2019, ASH 2019
Comparable Efficacy and Safety of Chinese Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Study
November 13, 2019, ASH2019
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
November 2019, Am Health Drug Benefits
Generic Imatinib Comparable to Original in Treatment of Chronic Myeloid Leukemia
October 11, 2019, Oncology Nurse Advisor
ASH report on news about generic imatinib
October 2, 2019, The CML Advocates Network
Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
February 19, 2019, Cancer Therapy Advisor
Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study
January 10, 2019, Haematologica
Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries
December 2, 2018, Cancer Therapy Advisor
Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study
December 1, 2018, ASH 2018
Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study
December 1, 2018, ASH 2018
Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study
December 2017, ASH2017
Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia
December 2017, ASH2017
Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia
July 2017, PubMed
Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing
April 2017, JCO Oncology Practice - ASCO
CML: First-line Generic Imatinib May Be Inferior to Branded Imatinib
February 23, 2017, Cancer Therapy Advisor
The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients
February 16, 2017, Clinical Lymphoma Myeloma& Leukemia
The Comparison of Efficacy Between Generic and Branded Imatinib in Achievement of Overall Survival and Cytogenetic Responses in CML Patients in Bosnia and Herzegovina
2016, Journal Blood
Outcome of Frontline Treatment with Generic Imatinib in Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A First Multicenter Study
December 3, 2016, ASH 2016
Incorporating Generic Imatinib Into Frontline Treatment for CML
October 1, 2016, OncLive
Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer
August 26, 2016, Nature
Safety and efficacy of imatinib generics
August 3, 2016, ecancer
Modest Price Cut Expected For Generic Version Of Cancer Pill Gleevec®
February 1, 2016, NPR
The generics vs. Gleevec®
December 21, 2015, The Canadian CML Network
Is generic mesilate of imatinib less inferior than Glivec® ? Analisys in brazilian cohort?
June 2015, European Hematology Association
Outcome of frontline treatment with generic imatinib according to ELN 2009 based national guidelines. Experience of frontline treatment with generic imatinib. Experience from university clinic of hematology, Clinical center of Serbia, Belgrade
June 2015, European Hematology Association
Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia
June 2015, 2015 ASCO Annual Meeting
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
March 26, 2015, Europe PMC
Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia
2015, Journal Blood
Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia
December 6, 2014, Blood
Does the use of generics of imatinib for chronic myeloid leukaemia jeopardise patient safety?
July 7, 2014, ecancer
If Novartis’s “improved” version of Glivec® is not more therapeutically efficacious, why is the Novartis decision such a big deal?
April 11, 2013, Havard Law
Canada: Pharma In Brief - Canada: Federal Court Upholds Validity Of GLEEVEC® Patent
February 27 2013, Mondaq
Europe set to approve first Glivec® generic - PMLiVE
October 22, 2012, PMLive